Device Trial Radar · NCT00506870
Benefit of Self-monitoring of Anticoagulation Instrument
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
919
Actual
Start
Jun 2007
Primary completion
Feb 2010
Study completion Feb 2010
Sponsor
- Lead sponsor
- University Hospital, BordeauxAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France; Roche Diagnostics GmbH; Biodis
- First posted
- Jul 25, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the benefit economic and medical of self-monitoring of coagulation compared with conventional follow-up of anticoagulation in a population recently fitted with mechanical heart valves.
Conditions
- Mechanical Prosthetic Heart Valve Implantation
- Patient Self Monitoring of Oral Anticoagulent Therapy
Interventions
INRatio / Coaguchek XSDevice
INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Economic and medical evaluation of self-monitoring of coagulation compared with conventional follow-up of anticoagulation in a population recently fitted with mechanical heart valves.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pôle Cardio-Thoracique - Hôpital Cardiologique du Haut-Lévêque - CHU de Bordeaux - Avenue de Magellan
Pessac, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.